BFM
ABUS icon

Boothbay Fund Management’s Arbutus Biopharma ABUS Stock Holding History

Boothbay Fund Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,624
Closed -$364K – 2013
2025
Q4 		$364K Sell
75,624
-234,427
-76% -$1.05M 0.01% 1328
2025
Q3 		$1.41M Buy
310,051
+47,774
+18% +$175K 0.02% 694
2025
Q2 		$810K Buy
262,277
+100,000
+62% +$332K 0.02% 759
2025
Q1 		$566K Hold
162,277
– – 0.01% 811
2024
Q4 		$531K Sell
162,277
-450,000
-73% -$1.66M 0.01% 851
2024
Q3 		$2.36M Hold
612,277
– – 0.05% 468
2024
Q2 		$1.89M Hold
612,277
– – 0.04% 518
2024
Q1 		$1.58M Buy
612,277
+158,649
+35% +$411K 0.03% 583
2023
Q4 		$1.13M Sell
453,628
-38,093
-8% -$74.6K 0.03% 688
2023
Q3 		$998K Hold
491,721
– – 0.02% 769
2023
Q2 		$1.13M Sell
491,721
-132,266
-21% -$344K 0.02% 779
2023
Q1 		$1.89M Sell
623,987
-88,680
-12% -$250K 0.04% 690
2022
Q4 		$1.66M Sell
712,667
-54,733
-7% -$131K 0.04% 669
2022
Q3 		$1.47M Buy
767,400
+215,132
+39% +$506K 0.04% 711
2022
Q2 		$1.5M Buy
552,268
+61,645
+13% +$158K 0.04% 666
2022
Q1 		$1.46M Buy
490,623
+31,981
+7% +$97.9K 0.03% 732
2021
Q4 		$1.78M Buy
458,642
+298,642
+187% +$1.16M 0.04% 517
2021
Q3 		$686K Buy
160,000
+100,000
+167% +$333K 0.02% 940
2021
Q2 		$182K Buy
60,000
+16,782
+39% +$52K 0.01% 1554
2021
Q1 		$144K Sell
43,218
-4,062
-9% -$15.7K 0.01% 1430
2020
Q4 		$168K Buy
47,280
+34,062
+258% +$119K 0.01% 1126
2020
Q3 		$41K Buy
+13,218
New +$40.2K ﹤0.01% 1003
2020
Q1 		– Sell
-21,261
Closed -$59K – 821
2019
Q4 		$59K Buy
+21,261
New +$34.4K 0.01% 793
2018
Q3 		– Sell
-48,000
Closed -$350K – 767
2018
Q2 		$350K Buy
+48,000
New +$286K 0.03% 434

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Boothbay Fund Management's ABUS Position: Q1 2026 in Review

Boothbay Fund Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 75,624 shares — an estimated $364K sold.

Boothbay Fund Management first reported a position in ABUS in Q2 2018 and held it in 24 quarters. The position peaked at $2.36M in Q3 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Boothbay Fund Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 75,624 Arbutus Biopharma shares in Q1 2026, an estimated $364K.
  • Boothbay Fund Management first reported a position in Arbutus Biopharma in Q2 2018 and held it in 24 quarters.
  • Boothbay Fund Management's Arbutus Biopharma position peaked at $2.36M in Q3 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.